Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2021-10-21 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma received a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products for orphan drug designation of their product QIXLEEF™. It discusses regulatory strategy, benefits of orphan drug designation, and background on the drug and condition it targets. There are no financial statements, earnings data, management discussion, or detailed regulatory filings. The document is an announcement of a regulatory milestone rather than a financial report or detailed regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a legal proceeding or M&A activity. It is a regulatory announcement about a drug designation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length (8678 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement. Confidence is high due to clear regulatory announcement nature and absence of financial or governance content.
2021-10-21 English
News release - English.pdf
Regulatory Filings
2021-10-14 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2021-10-14 English
Interim MD&A - English.pdf
Regulatory Filings
2021-10-14 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-10-14 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release announcing a major milestone for Tetra Bio-Pharma Inc., specifically the upcoming launch of REDUVO™, a cannabinoid-derived medicine. It discusses pre-launch activities, expected sales projections, and strategic plans. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content is focused on a business update and product launch rather than financial results or governance. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The document is a corporate announcement about a product launch and business development, which aligns best with a Capital/Financing Update (CAP) since it relates to company growth, product commercialization, and strategic initiatives that impact the company's capital and market position.
2021-10-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.